Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?

Area of Science:

• Oncology
• Stem Cell Biology
• Gastroenterology

Background:

• Leucine-rich repeat-containing G-protein coupled receptor (LGR5) is a marker for intestinal stem cells, potentiating Wnt/β-catenin signaling.
• LGR5+ cells can form self-organizing 'mini-guts' in vitro, modeling intestinal tissue.
• Wnt/β-catenin pathway deregulation is key in colorectal cancer (CRC) development, making LGR5 a potential therapeutic target.

Purpose of the Study:

• To review the dual roles of LGR5 in colorectal cancer (CRC) as both oncogenic and tumor suppressive.
• To highlight recent findings on the plasticity and redundancy of LGR5+ cells in intestinal cancer.
• To critically assess the therapeutic potential of targeting LGR5 in CRC treatment.

Main Methods:

• Literature review of studies investigating LGR5 expression and function in colorectal cancer.
• Analysis of research on LGR5+ cell plasticity and its implications in cancer progression.
• Evaluation of the therapeutic merit of targeting LGR5 in CRC based on current evidence.

Main Results:

• Conflicting results exist regarding the therapeutic value of LGR5 in CRC.
• CRC tumors contain LGR5+ subsets, maintaining some normal tissue architecture.
• Evidence suggests LGR5+ cells may exhibit plasticity or redundancy in intestinal cancer progression.

Conclusions:

• The role of LGR5 in CRC is complex, with both oncogenic and tumor-suppressive functions reported.
• The therapeutic targeting of LGR5 in CRC requires careful consideration due to cell plasticity.
• Further research is needed to clarify the precise role of LGR5 and its therapeutic implications in CRC.